Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Nov 25

PMID 38004560

Authors

Milan Beljkas

Aleksandra Ilic

Alen Cebzan

Branko Radovic

Nemanja Djokovic

Dusan Ruzic

Katarina Nikolic

Slavica Oljacic

Affiliations

Soon will be listed here.

Abstract

Histone deacetylases (HDACs) are the major regulators of the balance of acetylation of histone and non-histone proteins. In contrast to other HDAC isoforms, HDAC6 is mainly involved in maintaining the acetylation balance of many non-histone proteins. Therefore, the overexpression of HDAC6 is associated with tumorigenesis, invasion, migration, survival, apoptosis and growth of various malignancies. As a result, HDAC6 is considered a promising target for cancer treatment. However, none of selective HDAC6 inhibitors are in clinical use, mainly because of the low efficacy and high concentrations used to show anticancer properties, which may lead to off-target effects. Therefore, HDAC6 inhibitors with dual-target capabilities represent a new trend in cancer treatment, aiming to overcome the above problems. In this review, we summarize the advances in tumor treatment with dual-target HDAC6 inhibitors.

Citing Articles

Pioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents.

Beljkas M, Ruzic D, Djuric A, Vuletic A, Tchiehe G, Jallet C Future Med Chem. 2025; 17(4):393-407.

PMID: 39885716 PMC: 11834526. DOI: 10.1080/17568919.2025.2459589.

WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells.

Oliveira-Silva J, Oliveira L, Chiminazo C, Fonseca R, Souza C, Aissa A Cancer Chemother Pharmacol. 2025; 95(1):22.

PMID: 39821335 DOI: 10.1007/s00280-024-04731-y.

Histone deacetylase 6 inhibition prevents hypercholesterolemia-induced erectile dysfunction independent of changes in markers of autophagy.

Ihrig C, Montgomery M, Nomura Y, Nakano M, Pandey D, La Favor J Sex Med. 2025; 12(6):qfae096.

PMID: 39790566 PMC: 11717367. DOI: 10.1093/sexmed/qfae096.

Immunometabolism: signaling pathways, homeostasis, and therapeutic targets.

Xu R, He X, Xu J, Yu G, Wu Y MedComm (2020). 2024; 5(11):e789.

PMID: 39492834 PMC: 11531657. DOI: 10.1002/mco2.789.

Lysine deacetylase inhibitors have low selectivity in cells and exhibit predominantly off-target effects.

Bornes K, Moody M, Huckaba T, Benz M, McConnell E, Foroozesh M FEBS Open Bio. 2024; 15(1):94-107.

PMID: 39482806 PMC: 11705486. DOI: 10.1002/2211-5463.13896.

References

Kumar K, Das R, Thapa B, Rakhecha B, Srivastava S, Savita K . Dual targeted 2-Benzylideneindanone pendant hydroxamic acid group exhibits selective HDAC6 inhibition along with tubulin stabilization effect. Bioorg Med Chem. 2023; 86:117300. DOI: 10.1016/j.bmc.2023.117300. View

Kang Y, Nian H, Rajendran P, Kim E, Dashwood W, Pinto J . HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Cell Death Dis. 2014; 5:e1476. PMC: 4237248. DOI: 10.1038/cddis.2014.422. View

Park S, Jun J, Jeong K, Heo H, Sohn J, Lee H . Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep. 2011; 25(6):1677-81. DOI: 10.3892/or.2011.1236. View

Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y . HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res. 2004; 10(20):6962-8. DOI: 10.1158/1078-0432.CCR-04-0455. View

Chen C, Wei M, Wang C, Sun D, Liu P, Zhong X . The histone deacetylase HDAC1 activates HIF1α/VEGFA signal pathway in colorectal cancer. Gene. 2020; 754:144851. DOI: 10.1016/j.gene.2020.144851. View

Gajendran C, Tantry S, M N, Mohammed Z, Dewang P, Hallur M . Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer. PLoS One. 2023; 18(1):e0279063. PMC: 9810167. DOI: 10.1371/journal.pone.0279063. View

Jin H, Wang L, Bernards R . Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2022; 22(3):213-234. DOI: 10.1038/s41573-022-00615-z. View

Kalin J, Wu M, Gomez A, Song Y, Das J, Hayward D . Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018; 9(1):53. PMC: 5754352. DOI: 10.1038/s41467-017-02242-4. View

Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X . Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene. 2012; 32(5):599-609. PMC: 3371110. DOI: 10.1038/onc.2012.81. View

10.

Chen L, Meng S, Wang H, Bali P, Bai W, Li B . Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005; 4(9):1311-9. DOI: 10.1158/1535-7163.MCT-04-0287. View

11.

de Oliveira R, Sarkander J, Kazantsev A, Outeiro T . SIRT2 as a Therapeutic Target for Age-Related Disorders. Front Pharmacol. 2012; 3:82. PMC: 3342661. DOI: 10.3389/fphar.2012.00082. View

12.

Zuo Q, Wu W, Li X, Zhao L, Chen W . HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncol Rep. 2011; 27(3):819-24. DOI: 10.3892/or.2011.1553. View

13.

Zhang Y, Gao J, Wu J, Liu S, Zhang X, Lv X . Discovery of (S)-N-(thiazol-2-yl) pyrrolidine-1,2-dicarboxamide derivatives targeting PI3Ka/HDAC6 for the treatment of cancer. Bioorg Med Chem Lett. 2023; 94:129462. DOI: 10.1016/j.bmcl.2023.129462. View

14.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

15.

Bulut I, Lee A, Cevatemre B, Ruzic D, Belle R, Kawamura A . Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells. Cancers (Basel). 2022; 14(23). PMC: 9737972. DOI: 10.3390/cancers14236014. View

16.

Liu N, Rowley B, Bull C, Schneider C, Haegebarth A, Schatz C . BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013; 12(11):2319-30. DOI: 10.1158/1535-7163.MCT-12-0993-T. View

17.

Choi J, Kwon H, Yoon B, Kim J, Han S, Joo H . Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001; 92(12):1300-4. PMC: 5926683. DOI: 10.1111/j.1349-7006.2001.tb02153.x. View

18.

Wu T, Chen M, Chen I, Chen Y, Chen C, Wang C . Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment. J Adv Res. 2022; 46:159-171. PMC: 10105078. DOI: 10.1016/j.jare.2022.06.009. View

19.

Benson J, Chen Y, Cornell-Kennon S, Dorsch M, Kim S, Leszczyniecka M . Validating cancer drug targets. Nature. 2006; 441(7092):451-6. DOI: 10.1038/nature04873. View

20.

Park J, Han J . Targeting epigenetics for cancer therapy. Arch Pharm Res. 2019; 42(2):159-170. PMC: 6399185. DOI: 10.1007/s12272-019-01126-z. View